Artificial intelligence modeling of biomarker-based physiological age: Impact on phase 1 drug-metabolizing enzyme phenotypes

被引:0
|
作者
Bhat, Amruta Gajanan [1 ]
Ramanathan, Murali [1 ,2 ]
机构
[1] SUNY Buffalo, Univ Buffalo, Dept Pharmaceut Sci, Pharm 355, Buffalo, NY 14214 USA
[2] SUNY Buffalo, Dept Neurol, Univ Buffalo, Buffalo, NY USA
来源
关键词
TELOMERE LENGTH; PHARMACODYNAMICS; CAFFEINE;
D O I
10.1002/psp4.13273
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Age and aging are important predictors of health status, disease progression, drug kinetics, and effects. The purpose was to develop ensemble learning-based physiological age (PA) models for evaluating drug metabolism. National Health and Nutrition Examination Survey (NHANES) data were modeled with ensemble learning to obtain two PA models, PA-M1 and PA-M2. PA-M1 included body composition, blood and urine biomarkers, and disease variables as predictors. PA-M2 had blood and urine-derived variables as predictors. Activity phenotypes for cytochrome-P450 (CYP) CYP2E1, CYP1A2, CYP2A6, xanthine oxidase (XO), and N-acetyltransferase-2 (NAT-2) and telomere attrition were assessed. Bayesian networks were used to obtain mechanistic systems pharmacology model structures for PA. The study included n = 22,307 NHANES participants (51.5% female, mean age 46.0 years, range: 18-79 years). The PA-M1 and PA-M2 distributions had greater dispersion across age strata with a right skew for younger age strata and a left skew for older age strata. There was no evidence of algorithmic bias based on sex or race/ethnicity. Klotho, lean body mass, glycohemoglobin, and systolic blood pressure were the top four predictors for PA-M1. Glycohemoglobin, serum creatinine, total cholesterol, and urine creatinine were the top four predictors for PA-M2. The models also performed satisfactorily in independent validation. Model-predicted PA was associated with CYP2E1, CYP1A2, CYP2A6, XO, and NAT-2 activity. Telomere attrition was associated with greater PA-M1 and PA-M2. Ensemble learning models provide robust assessments of PA from easily obtained blood and urine biomarkers. PA is associated with Phase I drug-metabolizing enzyme phenotypes.
引用
收藏
页码:302 / 316
页数:15
相关论文
共 2 条
  • [1] Expression of glutathione S-transferase A1, a phase II drug-metabolizing enzyme in acute hepatic injury on mice
    Ma, Xin
    Liu, Fangping
    Li, Minmin
    Li, Zhi
    Lin, Yuexia
    Li, Rui
    Li, Changwen
    Chang, Yicong
    Zhao, Changwei
    Han, Qing
    Zhou, Qiong
    Zhao, Yulin
    Wang, Dening
    Liu, Jingli
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (04) : 3798 - 3804
  • [2] A physiological concentration of luteolin induces phase II drug-metabolizing enzymes through the ERK1/2 signaling pathway in HepG2 cells
    Kitakaze, Tomoya
    Makiyama, Atsushi
    Samukawa, Yumi
    Jiang, Songyan
    Yamashita, Yoko
    Ashida, Hitoshi
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 663 : 151 - 159